Evidence-based articles on HS research, daily life strategies, treatment options, mental health, and caregiver support.
Sonelokimab, an IL-17A/F nanobody from MoonLake Immunotherapeutics, achieved HiSCR75 in 42% of patients in the VELA Phase 3 trial, with a strong safety profile and a BLA submission pathway now underway. Here is what HS patients need to know about this advanced pipeline biologic.
Two-year data from the BE HEARD trials published in February 2026 showed that more than 85% of initial bimekizumab responders maintained their improvements, with 90% sustaining HiSCR50 and 86% maintaining quality of life gains. Here is what the long-term data means for patients.
A February 2026 study found that 54% of HS patients on GLP-1 receptor agonists for six months experienced less severe disease, with 52% reporting less pain and 53% less drainage. Here is what patients and clinicians need to know about this emerging treatment connection.
At Maui Derm 2026, Dr. Vivian Shi presented the updated HS treatment roadmap: combination medical and surgical strategies, topical ruxolitinib in Phase 3, IV infliximab for severe disease, and treatment targets shifting from HiSCR50 to HiSCR75. Here is what changed.
Updated for 2026, this comprehensive guide covers the full evidence base for dietary interventions in HS: brewer's yeast elimination, dairy reduction, low-glycemic eating, intermittent fasting, and the Mediterranean diet pattern. Includes a practical 7-day meal plan.
Brewer's yeast is one of the most studied dietary triggers for HS. Studies show that 30-50% of HS patients who eliminate it report improvement. This guide explains which foods contain brewer's yeast, how to do a proper elimination trial, and what the research actually shows.
Sonelokimab, an IL-17A/F nanobody from MoonLake Immunotherapeutics, achieved HiSCR75 in 42% of patients in the VELA Phase 3 trial, with a strong safety profile and a BLA submission pathway now underway. Here is what HS patients need to know about this advanced pipeline biologic.
Two-year data from the BE HEARD trials published in February 2026 showed that more than 85% of initial bimekizumab responders maintained their improvements, with 90% sustaining HiSCR50 and 86% maintaining quality of life gains. Here is what the long-term data means for patients.
A February 2026 study found that 54% of HS patients on GLP-1 receptor agonists for six months experienced less severe disease, with 52% reporting less pain and 53% less drainage. Here is what patients and clinicians need to know about this emerging treatment connection.
At Maui Derm 2026, Dr. Vivian Shi presented the updated HS treatment roadmap: combination medical and surgical strategies, topical ruxolitinib in Phase 3, IV infliximab for severe disease, and treatment targets shifting from HiSCR50 to HiSCR75. Here is what changed.
New data presented at Maui Derm 2026 confirmed that people with trisomy 21 are five times more likely to develop HS than the general population, and tend to develop it earlier and more severely. The recommendation is now to actively screen all Down syndrome patients for HS.
Brensocatib, an oral DPP1 inhibitor, completed Phase 2b enrollment in October 2025. Results are expected in 2026. If it works, brensocatib would represent an entirely new mechanism of action for HS, targeting neutrophil-driven inflammation in a way no current approved therapy does.
Updated for 2026, this comprehensive guide covers the full evidence base for dietary interventions in HS: brewer's yeast elimination, dairy reduction, low-glycemic eating, intermittent fasting, and the Mediterranean diet pattern. Includes a practical 7-day meal plan.
The HS treatment landscape changed significantly in 2024-2025 with the approval of bimekizumab and advancing Phase 3 data for povorcitinib. This updated guide walks through the current treatment ladder from topical care to biologics to surgery.
Brewer's yeast is one of the most studied dietary triggers for HS. Studies show that 30-50% of HS patients who eliminate it report improvement. This guide explains which foods contain brewer's yeast, how to do a proper elimination trial, and what the research actually shows.
A 2025 cross-sectional analysis of 1.8 million HS-related outpatient visits found hypertension in 15.7% of patients and obesity in 8.6%. Understanding and managing these comorbidities is now considered a core part of comprehensive HS care.
The STOP-HS Phase 3 trials reported in 2025 show that povorcitinib, an oral JAK1 inhibitor, achieved HiSCR50 in nearly 60% of patients at week 24. For people who prefer a pill to an injection, this could be a game-changer.
A 2024 survey of 110 HS patients found that one third reported dietary changes helped reduce their symptoms. This article reviews the current evidence on brewer's yeast elimination, dairy reduction, intermittent fasting, and anti-inflammatory eating patterns for HS.
Dairy and nightshades are frequently cited as HS triggers online, but what does the research actually say? This article reviews the current evidence, explains the proposed mechanisms, and gives practical guidance for patients considering elimination trials.
A wave of 2025 studies has deepened our understanding of how both the skin microbiome in HS tunnels and the gut microbiome contribute to disease activity. Here is what the latest science shows and what it means for treatment.
HS often means grieving the life you expected, the activities you can no longer do, the relationships affected, the career opportunities missed. This is a guide to processing that grief with compassion and honesty.
Several small studies and patient surveys suggest intermittent fasting may reduce HS flare frequency, possibly through weight loss, reduced insulin resistance, and lower systemic inflammation. This article reviews the evidence and practical considerations for HS patients.
When a parent has HS, children often notice the wounds, the pain, and the limitations. This guide helps parents have honest, age-appropriate conversations about HS with their kids.
New research from Duke University confirms what many women with HS have long known: the menstrual cycle has a measurable impact on disease activity. This article explains the hormonal mechanisms behind HS flares and the evidence-based strategies for managing them.
Heat and sweating are major HS triggers. This guide gives you practical strategies for managing HS during summer, from cooling techniques to clothing choices to travel tips.
Mindfulness-based approaches have strong evidence for reducing chronic pain and improving quality of life. This guide explains how to apply them specifically to the HS experience.
Caring for someone with a chronic painful condition takes a toll. This guide helps caregivers recognize burnout, set healthy boundaries, and find their own support.
HS carries the highest Dermatology Life Quality Index score of any skin condition, averaging 18 out of 30. Depression and anxiety are significantly more common in HS patients than in the general population. This guide explains the connection and outlines evidence-based strategies for getting support.
Doxycycline is one of the most commonly prescribed antibiotics for HS. This guide covers how it works, dosing, side effects, and how to maximize its effectiveness as part of a broader treatment plan.
From requesting accommodations to managing flares during work hours, this guide covers everything you need to know about navigating your career with HS, including your legal rights under the ADA.
Supporting a loved one with HS means understanding the condition, knowing what helps and what does not, and taking care of yourself too. This guide is for the people who love HS patients.
What you wear makes a real difference with HS. This guide covers the best fabrics, styles, and brands for minimizing friction, managing drainage, and staying comfortable throughout the day.
Adalimumab (Humira) was the first biologic approved for HS in 2015. Now with biosimilars available, it remains a widely used first-line biologic. This guide covers how it works, what to expect, injection technique, side effects, and what to do if it stops working.
The FDA approved bimekizumab (Bimzelx) for moderate-to-severe HS in November 2024, making it the third biologic approved for the condition. A 2025 network meta-analysis identified it as the most efficacious biologic currently available for HS. Here is what the approval means for patients.
Free HS Survival Starter Kit